Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m) & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

ALK (Anaplastic Lymphoma Kinase) inhibitors are the standard-of-care treatment for metastatic Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m) in both the first- and second-line settings.

References:
Bronte et al. 2021 Expert Review of Anticancer Therapy 21: 809-817
Moskovitz et al. 2022 The Oncologist 27: e76-e84

…

ALK Inhibitors or Chemotherapy for Third Line in ALK- positive NSCLC? Real-world Data
Moskovitz et al. 2022 The Oncologist 27: e76-e84
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy
Bronte et al. 2021 Expert Review of Anticancer Therapy 21: 809-817
Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives
Ryser et al. 2019 Current Opinion in Oncology 31: 8-12

7/1/2026